Tumour exosomes as a source of liquid biopsy: the future of diagnosis in oncology

https://youtu.be/Q87npv5qAQc

The use of tumour exosomes as a source of liquid biopsy has become one of the most promising advances in the diagnosis and monitoring of cancer. Tumour cells release exosomes, extracellular vesicles that circulate in biological fluids such as blood, urine, or saliva, carrying key molecular information about the tumour.

Thanks to their abundant presence and stable content (proteins, RNA, DNA, and lipids), exosomes enable clinicians and researchers to capture the tumour’s dynamic state non-invasively, representing a revolution compared to traditional biopsies.

What is a liquid biopsy and why does it matter?

A liquid biopsy refers to the detection and analysis of tumour biomarkers in bodily fluids without the need for invasive procedures. This technique allows:

• Information to be obtained on tumours in multiple locations without surgical biopsies.
• Repeated sampling to monitor response to treatment.
• Detect relapses or disease progression in real time.

Within liquid biopsy, exosomes differ from other biomarkers (such as circulating tumour DNA or circulating tumour cells) due to their abundance and stability in the blood.

Why are tumour exosomes so valuable in oncology?

1. Stability and abundance

Exosomes secreted by tumour cells are protected by a lipid membrane that preserves their molecular content, preventing their degradation in the bloodstream. This characteristic makes them more stable than other traditional biomarkers.

2. Representative information about the tumour

Exosomes contain RNA, proteins and other markers that reflect the biological state of the tumour that produced them. This allows the identification of molecular signatures associated with specific pathologies, disease stages or therapeutic resistance.

3. Real-world clinical applications

Exosome-based liquid biopsies can be used for:

• Early cancer diagnosis, even before tumours are detectable by imaging.
• Treatment monitoring, such as immunotherapy or targeted therapies.
• Recurrence detection through molecular profiling in blood.

Specific applications in different types of cancer

Clinical studies indicate that tumour exosomes can be used as specific biomarkers for different types of cancer, for example:

• Lung cancer: exosomal miRNA profiles that distinguish patients from healthy individuals.
• Breast cancer: detection of miR-1246 and other miRNAs associated with tumour progression.
• Pancreatic cancer: a combination of free and exosomal miRNAs improves early detection.

This approach demonstrates that exosomes can provide highly specific diagnostic and prognostic information for each tumour type, reinforcing their utility in precision medicine.

Current challenges and future prospects

Although the potential of exosomes is enormous, there are challenges to be resolved before their widespread clinical use:

• Standardisation of isolation and analysis methods.
• Validation of exosomal biomarkers in large patient cohorts.
• Integration of clinical data with advanced molecular analysis.

Research continues to develop technologies that enable the isolation and characterisation of exosomes with high precision and reproducibility, bringing exosome-based liquid biopsy ever closer to clinical practice.

Conclusion

Tumour exosomes in liquid biopsy represent a unique opportunity to transform the diagnosis and management of cancer. Their ability to provide detailed molecular information in a minimally invasive manner positions them as a key tool in precision oncology. As researchers overcome technical challenges and validate specific biomarkers, clinicians can significantly improve the management of cancer patients.